The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment
Table 1
Baseline characteristics by group.
Naïve group
Teriparatide group
Bisphosphonate group
value
Number
15
15
10
Age (y)
80.9 ± 2.3
80.0 ± 8.4
74.1 ± 6.4
0.055
BMI (kg/m2)
25.5 ± 6.3
24.9 ± 5.8
24.1 ± 3.8
0.301
BMD: femur (g/cm2)
0.519 ± 0.150
0.441 ± 0.102a
0.511 ± 0.001
<0.05a
BMD: lumbar spine (g/cm2)
0.709 ± 0.095
0.648 ± 0.144a
0.693 ± 0.045
<0.05a
Serum calcium (g/dl)
9.5 ± 0.4
9.6 ± 0.5
9.3 ± 0.3
0.097
eGFR (ml/min/1.73 m2)
64.3 ± 18.7
62.4 ± 20.1
76.1 ± 12.9
0.053
P1NP (ng/ml)
53.2 ± 18.5
77.5 ± 19.1
16.7 ± 5.4a
<0.05a
TRACP-5b (mU/dl)
321.5 ± 116.6
463.0 ± 111.6
211.7 ± 56.9a
<0.05a
25OHD (ng/ml)
11.7 ± 6.5
10.0 ± 5.6a
16.5 ± 5.3
<0.05a
Previous fracture
None
None
None
Values are expressed as means and standard deviation. aANOVA. BMI: body mass index, BMD: bone mineral density, eGFR: estimated glomerular filtration rate, P1NP: procollagen 1 N-terminal propeptide, TRACP-5b: tartrate-resistant acid phosphatase 5b, and 25OHD: 25-hydroxyvitamin D.